Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents

Ophthalmology. 1998 Nov;105(11):2028-34. doi: 10.1016/S0161-6420(98)91120-4.

Abstract

Objective: To review the safety and efficacy of cyclosporine in the treatment of children with severe bilateral sight-threatening intermediate uveitis or panuveitis.

Design/participants: A retrospective chart review was performed on all children younger than 18 years of age with chronic bilateral sight-threatening uveitis who were treated with cyclosporine.

Main outcome measures: Assessment of the therapeutic efficacy and development of adverse effects of cyclosporine after 6 months, 2 years, and 4 years of therapy was performed.

Results: Between 1983 and 1992, 15 children and adolescents were treated with cyclosporine. After 6 months, visual acuity improved or stabilized in 82.1% of eyes, while median vitreous inflammation decreased from 2.0 to 0.5. After 2 and 4 years, visual acuity improved or stabilized in 64% and 75% of eyes, respectively. Median vitreous inflammation remained 0.5 after 2 and 4 years of therapy. Mean creatinine clearance and hemoglobin values decreased and serum creatinine increased after 6 months. After 2 years, only mean hemoglobin values remained decreased. After 4 years, no significant differences were noted in any of the laboratory studies. The most frequently noted side effects included transient increases in serum creatinine in 53%, gingival hyperplasia in 40%, and hirsutism in 20% of patients.

Conclusions: The authors' results suggest that cyclosporine is a safe and effective therapy for the treatment of children with severe bilateral sight-threatening intermediate uveitis or panuveitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Creatinine / blood
  • Cyclosporine / adverse effects
  • Cyclosporine / therapeutic use*
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Panuveitis / blood
  • Panuveitis / complications
  • Panuveitis / drug therapy*
  • Retrospective Studies
  • Safety
  • Treatment Outcome
  • Uveitis, Intermediate / blood
  • Uveitis, Intermediate / complications
  • Uveitis, Intermediate / drug therapy*
  • Vision Disorders / blood
  • Vision Disorders / etiology
  • Visual Acuity

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Creatinine